Ceftazidime and Zolpidem tartrate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Ceftazidime and Zolpidem tartrate. Common interactions include body temperature increased among females and pancytopenia among males.

The phase IV clinical study analyzes what interactions people who take Ceftazidime and Zolpidem tartrate have. It is created by eHealthMe based on reports of 35 people who take Ceftazidime and Zolpidem tartrate from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.



On Oct, 03, 2022

35 people who take Ceftazidime and Zolpidem tartrate together, and have interactions are studied.


What is Ceftazidime?

Ceftazidime has active ingredients of ceftazidime. eHealthMe is studying from 8,871 Ceftazidime users for its effectiveness, alternative drugs and more.

What is Zolpidem tartrate?

Zolpidem tartrate has active ingredients of zolpidem tartrate. It is often used in insomnia. eHealthMe is studying from 28,219 Zolpidem tartrate users for its effectiveness, alternative drugs and more.

Number of Ceftazidime and Zolpidem tartrate reports submitted per year:

Ceftazidime and Zolpidem tartrate drug interactions.

Common Ceftazidime and Zolpidem Tartrate drug interactions by gender *:

female:

  1. Body temperature increased
  2. Cerebral infarction
  3. Dehydration
  4. Device related infection
  5. Dysarthria
  6. Dyspnoea
  7. Gait abnormal
  8. Gastrointestinal haemorrhage
  9. Haematoma
  10. Headache

male:

  1. Pancytopenia
  2. White blood cell count decreased
  3. Blood alkaline phosphatase increased
  4. Brain oedema
  5. Hyperbilirubinaemia
  6. Mental status changes
  7. Pneumonia
  8. Pyrexia
  9. Abdominal abscess
  10. Activated partial thromboplastin time prolonged

Common Ceftazidime and Zolpidem Tartrate drug interactions by age *:

0-1:

n/a

2-9:

n/a

10-19:

  1. Alanine aminotransferase increased
  2. Blood alkaline phosphatase increased
  3. Bronchopulmonary aspergillosis
  4. Cardiomegaly
  5. Cholelithiasis
  6. Cns ventriculitis
  7. Coagulopathy
  8. Convulsion
  9. Depressed level of consciousness
  10. Encephalopathy

20-29:

  1. Infective pulmonary exacerbation of cystic fibrosis

30-39:

  1. Anaemia
  2. Anal haemorrhage
  3. Dehydration
  4. Kaposi's sarcoma
  5. Non-hodgkin's lymphoma
  6. Pancytopenia
  7. Pneumocystis jiroveci pneumonia
  8. Productive cough
  9. Rales
  10. Rhonchi

40-49:

  1. Blood pressure decreased
  2. Body temperature increased
  3. Cough
  4. Cytomegalovirus antibody positive
  5. Diarrhoea
  6. Epstein-barr virus antibody positive
  7. Gamma-glutamyltransferase increased
  8. General physical health deterioration
  9. Hepatic enzyme increased
  10. Infection

50-59:

  1. Acidosis
  2. Acute respiratory distress syndrome
  3. Blood pressure decreased
  4. Heart rate decreased
  5. Hypoxia
  6. Pneumonia bacterial

60+:

  1. Respiratory failure
  2. Abdominal abscess
  3. Pseudomembranous colitis
  4. Pseudomonal sepsis
  5. Pulmonary alveolar haemorrhage
  6. Respiratory arrest
  7. White blood cell count decreased
  8. Wound dehiscence
  9. Abnormal behaviour
  10. Adrenal insufficiency

Common conditions people have *:

  1. Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 4 people, 11.43%
  2. B Precursor Type Acute Leukaemia (lymphoid cancer): 4 people, 11.43%
  3. Cystic Fibrosis (disease of the secretary glands): 3 people, 8.57%
  4. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 2 people, 5.71%
  5. High Blood Pressure: 2 people, 5.71%
  6. Febrile Neutropenia (fever with reduced white blood cells): 2 people, 5.71%
  7. Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 2 people, 5.71%

* Approximation only. Some reports may have incomplete information.

Do you take Ceftazidime and Zolpidem tartrate?

Personalize this study to your gender and age

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.



Related publications that referenced our studies

Related studies

Alternative drugs to, pros and cons of the 2 drugs:

Browse all drug interactions of Ceftazidime and Zolpidem tartrate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Ceftazidime interactions:

Browse all interactions between Ceftazidime and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Common Zolpidem tartrate interactions:

Browse all interactions between Zolpidem tartrate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on ceftazidime and zolpidem tartrate (the active ingredients of Ceftazidime and Zolpidem tartrate, respectively), and Ceftazidime and Zolpidem tartrate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study. Patients in the study may take other drugs besides Ceftazidime and Zolpidem tartrate.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe: